April 28, 2022

The migraine field has seen its share of recent successes in the treatment realm, particularly with drugs targeting either calcitonin gene-related peptide (CGRP), a peptide elevated in the serum during migraine attacks, or the CGRP receptor. Yet only about half of patients improve with anti-CGRP therapies, underscoring the need for new drug targets…

Read the full news story on the Migraine Science Collaborative